R&D News | pharmaphorum

News

Novo Nordisk swells alliance with AI firm Valo Health

Novo Nordisk almost doubles the scale of its R&D alliance with AI specialist Valo Health, which now spans 20 programmes and a value of up to $4.6bn.

News

Galapagos' chief executive Paul Stoffels

Galapagos unveils plan to split, hiving off its drugs unit

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its drug development and cell therapy operations.

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

News

Aviceda raises $207.5m for eye drug, and other financings

Our round-up of recent biotech financings includes a big round for Aviceda, with Orbis, Alebund, XyloCor, and PrimeGene also raising additional cash.

News

combination of directions for booted feet, two arrows

J&J says Rybrevant combo has survival edge over Tagrisso

Rybrevant plus Lazcluze extended median OS by more than a year compared to Tagrisso in the MARIPOSA trial in treatment-naive, EGFR-mutated NSCLC.

News

GSK bags breakthrough status for bone cancer drug

GSK has claimed its second breakthrough designation from the FDA for B7-H3-targeted ADC, this time in osteosarcoma.

Novo Nordisk swells alliance with AI firm Valo Health

Galapagos unveils plan to split, hiving off its drugs unit

11 blockbuster drugs to look out for in 2025

Aviceda raises $207.5m for eye drug, and other financings

J&J says Rybrevant combo has survival edge over Tagrisso

GSK bags breakthrough status for bone cancer drug

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks